Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of L-citrulline versus placebo in patients undergoing surgery for congenital heart defects. Eligible patients undergoing repair of a large unrestrictive ventricular septal defect (VSD), a partial or complete atrioventricular septal defect (AVSD), or an ostium primum atrial septal defect (primum ASD) will be eligible for enrollment.


Clinical Trial Description

This is a randomized, double-blind, placebo controlled, multicenter study that will compare the efficacy and safety of L- citrulline versus placebo in patients undergoing surgery for congenital heart defects. Eligible patients undergoing repair of a large unrestrictive ventricular septal defect (VSD), a partial or complete atrioventricular septal defect (AVSD), or an ostium primum atrial septal defect (primum ASD) will be eligible for enrollment. Each enrolled patient will be randomized to receive either L citrulline or placebo throughout all administrations in the study. Patients will receive: 1. an L-citrulline bolus of 150 mg/kg or placebo at the initiation of cardiopulmonary bypass 2. the addition L-citrulline or placebo to maintain a steady state target concentration of approximately 100 μmol/L of L-Citrulline or placebo during cardiopulmonary bypass 3. an L-citrulline bolus of 10 mg/kg or placebo 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hour continuous L-citrulline infusion or placebo for up to 48 hours post-first dose. The infusion rate will be adjusted (up or down titration of drug infusion) to achieve a target steady state concentration of 100 µmol/L. The study drug or placebo infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever occurs first. Patients will be followed until Day 28 or discharge from the hospital, whichever occurs first. For patients discharged prior to Day 28, a final assessment via telephone will be conducted at Day 28. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05253209
Study type Interventional
Source Asklepion Pharmaceuticals, LLC
Contact Gurdyal Kalsi, MD, MFPM
Phone +1 410.736.3750
Email gurdyal.kalsi@asklepionpharm.com
Status Recruiting
Phase Phase 3
Start date June 29, 2022
Completion date February 10, 2024

See also
  Status Clinical Trial Phase
Completed NCT03684161 - Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect
Completed NCT01120964 - Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol Phase 1/Phase 2
Completed NCT02914652 - The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects. Phase 4
Recruiting NCT05939713 - Cera™ VSD Occluder Post Market Clinical Follow-up
Recruiting NCT05688670 - Regional Anesthesia Following Pediatric Cardiac Surgery Phase 4
Completed NCT02138435 - Longterm Outcome After Ventricular Septal Defect Closure N/A
Not yet recruiting NCT06298344 - The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease Early Phase 1
Completed NCT00556361 - Use of Ketamine Prior to Cardiopulmonary Bypass in Children Phase 2
Completed NCT05200910 - The Effect of Transcatheter VSD Closure on Children's Appetite, Hormones and Growth
Recruiting NCT03127748 - Cardiac Function After Transcatheter VSD Closure N/A
Enrolling by invitation NCT06214182 - Immune Heterogeneity Before and After Cardiopulmonary Bypass in Children
Active, not recruiting NCT04667455 - Improving Care for Children With Congenital Heart Disease. N/A
Active, not recruiting NCT04417712 - Lifetech MFO Post-Market Clinical Follow-Up Study
Completed NCT01313832 - The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension N/A
Active, not recruiting NCT04017975 - Optical Tissue Identification for Myocardial Architecture Phase 2
Completed NCT01915277 - A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics Phase 1
Recruiting NCT03941691 - A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure N/A
Completed NCT04859036 - The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters